A new study published in JACC: Cardiovascular Interventions indicates that the transradial percutaneous coronary intervention (PCI) is associated with an average cost of US$13,389 with same-day discharge compared with US$17,076 for the transfemoral approach with at least one night of hospitalisation—resulting in a cost savings of about US$3,700 for outpatients who undergo coronary angioplasty procedures with the transradial approach. Independent of the length of stay, the transradial approach costs about US$900 less than the transfemoral approach on average.
According to Reuters, Boston Scientific is recalling all ranges of its transcatheter aortic valve implantation (TAVI) device Lotus. The news agency reports that the recall relates to a locking mechanism problem and has sent the company’s shares down by “as much as 7.4%”. Boston Scientific has also apparently delayed submitting the US marketing application for its Lotus Edge device.
Teleflex Incorporated has completed its previously announced acquisition of Vascular Solutions.
Cardiovascular Systems (CSI) has released one-year results from its Coronary Orbital Atherectomy System Study (COAST) in a late-breaking presentation at the 2017 Cardiovascular Research Technologies (CRT) conference in Washington, DC, USA. The researchers observed 77.8% freedom from major adverse cardiac events (MACE) at one year, following from 85% freedom at 30 days.
Ki Hong Choi (Division of Cardiology, Department of Medicine, Cardiac and Vascular Centre, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea) and others report in EuroIntervention that percutaneous coronary intervention (PCI) is not associated with a significant reduction in cardiac death compared with medical management in diabetic patients with chronic total occlusions. However, PCI in this cohort of patients does reduce the risk of major adverse cardiac events (MACE).
Biosensors has announced that the first patient has been enrolled in LEADERS FREE II—the BioFreedom pivotal study, which is being conducted under an investigational device exemption (IDE). The study includes sites in the USA, Canada, Denmark, France Germany, Italy, and the UK and will be evaluating the use of the BioFreedom drug-coated stent. A press release reports that the stent has been implanted to date in more than 150,000 patients in more than 40 countries outside the USA.
Biotronik’s Pro-Kinetic Energy bare metal stent has received FDA approval, which is based on the results of the BIOHELIX-I clinical study. Therefore, the stent, which a press release reports has already been used to treat more than 650,000 patients worldwide, is now available in the USA.
A study, published in Catheterization and Cardiovascular Interventions, found that most patients undergoing coronary angiography believe that—following percutaneous coronary intervention (PCI)—avoiding dual antiplatelet therapy (DAPT) drawbacks is as important as avoiding repeat revascularisation. It also found that 85% of those who go on to have PCI receive a drug-eluting stent, which suggests that the physician treating them does not take into account their preference to avoid the drawbacks of DAPT (ie. implanting a bare metal stent may be more in line with their wishes).
Researchers have projected that aggressively lowering blood pressure could help prevent more than 100,000 deaths in the USA each year.
The German Institute for the Hospital Remuneration System (InEK) has renewed Status 1—the highest of four levels—for SentreHEART’s Lariat and Eclipse left atrial appendage closure devices across 50 hospitals under the NUB innovation programme.
Symetis, a medical technology company specialising in the development, manufacturing and marketing of percutaneous heart valve replacement solutions for the treatment of severe cardiac valve conditions, has purchased Middle Peak Medical, a private US and German medical device company focused on developing minimally invasive novel solutions for unmet needs in the treatment of mitral valve regurgitation. The acquisition marks Symetis’ first expansion from the TAVI space into the broader structural heart segment.
Medtronic has announced the launch of Medtronic Impact in the Europe, Middle East & Africa regions.
The UK’s National Institute for Health and Care Excellence (NICE) has issued guidance today for use of the HeartFlow FFRct Analysis to help determine the cause of stable chest pain in patients. Developed by HeartFlow, the HeartFlow FFRct Analysis is the first non-invasive technology to provide insight into both the extent of coronary artery disease and the impact that disease has on blood flow to the heart.
A new test that predicts an individual’s risk for developing cardiovascular disease has been launched today by Everist Health.
In the largest epidemiological study conducted in the developing world, researchers found that as exposures to fine particulate air pollution in 272 Chinese cities increase, so do deaths from cardiovascular and respiratory diseases.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos